Direct Impact SDG: 3. Good Health and Well-being
The production of local biotechnological medicine
Health Care
Biotechnology and Pharmaceuticals
Investments in biotechnology medicine production will increase the value added from medicine and make essential pharmaceuticals more readily accessible for Turkish patients.
Indicative Return
More than 25%
Investment Timeframe
Long Term (10+ years)
Market Size
More than USD 1 billion
Telehealth and remote diagnosis
Health Care
Medical Technology
Investments in telehealth models will improve access to healthcare services for the population as a whole and reduce the pressure on healthcare facilities, minimizing the risk of exposure for patients and healthcare workers during viral outbreaks.
Indicative Return
More than 25%
Investment Timeframe
Short Term (0–5 years)
Market Size
More than USD 1 billion
PPE Production as a Response to COVID-19 Pandemic and Future Crises
Consumer Goods
Apparel and Textiles
Investing in local businesses which manufacture disposable or washable face masks will create an efficient supply of PPEs for daily use and for health workers, reducing the risk of contagion during pandemics.
Indicative Return
15% – 20%
Investment Timeframe
Short Term (0–5 years)
Market Size
More than USD 1 billion
Investing in Hospitals/Clinics to Provide Healthcare Services
Health Care
Health Care Providers
This IOA will increase access to high-quality healthcare services for the populations of neighboring countries.
Indicative Return
10% – 15%
Investment Timeframe
Medium Term (5–10 years)
Market Size
More than USD 1 billion
Wearable Medical Technologies for Better Health
Technology and Communications
Technology
This IOA will facilitate early diagnosis and reduce the pressure on healthcare facilities, contributing positively to health and wellbeing indicators
Indicative Return
More than 25%
Investment Timeframe
Medium Term (5–10 years)
Market Size
More than USD 1 billion